カテゴリー： QYResearch, 世界, 医療/バイオ

世界のセツキシマブバイオシミラー市場インサイト及び予測（100 mg / 50 mL注射、200 mg /100mL注射）

◆英語タイトル：Global Cetuximab Biosimilar Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JL3853）◆商品コード：QY22JL3853
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：92
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、セツキシマブバイオシミラーのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にセツキシマブバイオシミラーの世界市場のxxx％を占める「100 mg / 50 mL注射」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「転移性結腸直腸がん」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
セツキシマブバイオシミラーの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのセツキシマブバイオシミラー市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

セツキシマブバイオシミラーのグローバル主要企業には、Actavis、Amgen、Celltrion、Pfizer、Bio X Cell、Wuhan Dima Biotechnology、Guangdong ANNPO Biotechnologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

セツキシマブバイオシミラー市場は、種類と用途によって区分されます。世界のセツキシマブバイオシミラー市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
100 mg / 50 mL注射、200 mg /100mL注射

【用途別セグメント】
転移性結腸直腸がん、転移性乳がん、非小細胞肺がん、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- セツキシマブバイオシミラー製品概要
- 種類別市場（100 mg / 50 mL注射、200 mg /100mL注射）
- 用途別市場（転移性結腸直腸がん、転移性乳がん、非小細胞肺がん、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界のセツキシマブバイオシミラー販売量予測2017-2028
- 世界のセツキシマブバイオシミラー売上予測2017-2028
- セツキシマブバイオシミラーの地域別販売量
- セツキシマブバイオシミラーの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別セツキシマブバイオシミラー販売量
- 主要メーカー別セツキシマブバイオシミラー売上
- 主要メーカー別セツキシマブバイオシミラー価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（100 mg / 50 mL注射、200 mg /100mL注射）
- セツキシマブバイオシミラーの種類別販売量
- セツキシマブバイオシミラーの種類別売上
- セツキシマブバイオシミラーの種類別価格
・用途別市場規模（転移性結腸直腸がん、転移性乳がん、非小細胞肺がん、その他）
- セツキシマブバイオシミラーの用途別販売量
- セツキシマブバイオシミラーの用途別売上
- セツキシマブバイオシミラーの用途別価格
・北米市場
- 北米のセツキシマブバイオシミラー市場規模（種類別、用途別）
- 主要国別のセツキシマブバイオシミラー市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのセツキシマブバイオシミラー市場規模（種類別、用途別）
- 主要国別のセツキシマブバイオシミラー市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のセツキシマブバイオシミラー市場規模（種類別、用途別）
- 主要国別のセツキシマブバイオシミラー市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のセツキシマブバイオシミラー市場規模（種類別、用途別）
- 主要国別のセツキシマブバイオシミラー市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのセツキシマブバイオシミラー市場規模（種類別、用途別）
- 主要国別のセツキシマブバイオシミラー市場規模（トルコ、サウジアラビア）
・企業情報
Actavis、Amgen、Celltrion、Pfizer、Bio X Cell、Wuhan Dima Biotechnology、Guangdong ANNPO Biotechnology
・産業チェーン及び販売チャネル分析
- セツキシマブバイオシミラーの産業チェーン分析
- セツキシマブバイオシミラーの原材料
- セツキシマブバイオシミラーの生産プロセス
- セツキシマブバイオシミラーの販売及びマーケティング
- セツキシマブバイオシミラーの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- セツキシマブバイオシミラーの産業動向
- セツキシマブバイオシミラーのマーケットドライバー
- セツキシマブバイオシミラーの課題
- セツキシマブバイオシミラーの阻害要因
・主な調査結果

Market Analysis and Insights: Global Cetuximab Biosimilar Market
Due to the COVID-19 pandemic, the global Cetuximab Biosimilar market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, 100 mg/50 mL Injection accounting for % of the Cetuximab Biosimilar global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Metastatic colorectal cancer segment is altered to an % CAGR throughout this forecast period.
China Cetuximab Biosimilar market size is valued at US$ million in 2021, while the US and Europe Cetuximab Biosimilar are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cetuximab Biosimilar landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Cetuximab Biosimilar include Actavis, Amgen, Celltrion, Pfizer, Bio X Cell, Wuhan Dima Biotechnology and Guangdong ANNPO Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cetuximab Biosimilar Scope and Segment
Cetuximab Biosimilar market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cetuximab Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
100 mg/50 mL Injection
200 mg/100 mL Injection
Segment by Application
Metastatic colorectal cancer
Metastatic breast cancer
Non-small cell lung cancer
Other
By Company
Actavis
Amgen
Celltrion
Pfizer
Bio X Cell
Wuhan Dima Biotechnology
Guangdong ANNPO Biotechnology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Cetuximab Biosimilar Product Introduction
1.2 Market by Type
1.2.1 Global Cetuximab Biosimilar Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 100 mg/50 mL Injection
1.2.3 200 mg/100 mL Injection
1.3 Market by Application
1.3.1 Global Cetuximab Biosimilar Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Metastatic colorectal cancer
1.3.3 Metastatic breast cancer
1.3.4 Non-small cell lung cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Cetuximab Biosimilar Sales Estimates and Forecasts 2017-2028
2.2 Global Cetuximab Biosimilar Revenue Estimates and Forecasts 2017-2028
2.3 Global Cetuximab Biosimilar Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Cetuximab Biosimilar Sales by Region
2.4.1 Global Cetuximab Biosimilar Sales by Region (2017-2022)
2.4.2 Global Sales Cetuximab Biosimilar by Region (2023-2028)
2.5 Global Cetuximab Biosimilar Revenue by Region
2.5.1 Global Cetuximab Biosimilar Revenue by Region (2017-2022)
2.5.2 Global Cetuximab Biosimilar Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Cetuximab Biosimilar Sales by Manufacturers
3.1.1 Global Top Cetuximab Biosimilar Manufacturers by Sales (2017-2022)
3.1.2 Global Cetuximab Biosimilar Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cetuximab Biosimilar in 2021
3.2 Global Cetuximab Biosimilar Revenue by Manufacturers
3.2.1 Global Cetuximab Biosimilar Revenue by Manufacturers (2017-2022)
3.2.2 Global Cetuximab Biosimilar Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Cetuximab Biosimilar Revenue in 2021
3.3 Global Cetuximab Biosimilar Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Cetuximab Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Cetuximab Biosimilar Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cetuximab Biosimilar Sales by Type
4.1.1 Global Cetuximab Biosimilar Historical Sales by Type (2017-2022)
4.1.2 Global Cetuximab Biosimilar Forecasted Sales by Type (2023-2028)
4.1.3 Global Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
4.2 Global Cetuximab Biosimilar Revenue by Type
4.2.1 Global Cetuximab Biosimilar Historical Revenue by Type (2017-2022)
4.2.2 Global Cetuximab Biosimilar Forecasted Revenue by Type (2023-2028)
4.2.3 Global Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
4.3 Global Cetuximab Biosimilar Price by Type
4.3.1 Global Cetuximab Biosimilar Price by Type (2017-2022)
4.3.2 Global Cetuximab Biosimilar Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Cetuximab Biosimilar Sales by Application
5.1.1 Global Cetuximab Biosimilar Historical Sales by Application (2017-2022)
5.1.2 Global Cetuximab Biosimilar Forecasted Sales by Application (2023-2028)
5.1.3 Global Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
5.2 Global Cetuximab Biosimilar Revenue by Application
5.2.1 Global Cetuximab Biosimilar Historical Revenue by Application (2017-2022)
5.2.2 Global Cetuximab Biosimilar Forecasted Revenue by Application (2023-2028)
5.2.3 Global Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
5.3 Global Cetuximab Biosimilar Price by Application
5.3.1 Global Cetuximab Biosimilar Price by Application (2017-2022)
5.3.2 Global Cetuximab Biosimilar Price Forecast by Application (2023-2028)
6 North America
6.1 North America Cetuximab Biosimilar Market Size by Type
6.1.1 North America Cetuximab Biosimilar Sales by Type (2017-2028)
6.1.2 North America Cetuximab Biosimilar Revenue by Type (2017-2028)
6.2 North America Cetuximab Biosimilar Market Size by Application
6.2.1 North America Cetuximab Biosimilar Sales by Application (2017-2028)
6.2.2 North America Cetuximab Biosimilar Revenue by Application (2017-2028)
6.3 North America Cetuximab Biosimilar Market Size by Country
6.3.1 North America Cetuximab Biosimilar Sales by Country (2017-2028)
6.3.2 North America Cetuximab Biosimilar Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Cetuximab Biosimilar Market Size by Type
7.1.1 Europe Cetuximab Biosimilar Sales by Type (2017-2028)
7.1.2 Europe Cetuximab Biosimilar Revenue by Type (2017-2028)
7.2 Europe Cetuximab Biosimilar Market Size by Application
7.2.1 Europe Cetuximab Biosimilar Sales by Application (2017-2028)
7.2.2 Europe Cetuximab Biosimilar Revenue by Application (2017-2028)
7.3 Europe Cetuximab Biosimilar Market Size by Country
7.3.1 Europe Cetuximab Biosimilar Sales by Country (2017-2028)
7.3.2 Europe Cetuximab Biosimilar Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Cetuximab Biosimilar Market Size by Type
8.1.1 Asia Pacific Cetuximab Biosimilar Sales by Type (2017-2028)
8.1.2 Asia Pacific Cetuximab Biosimilar Revenue by Type (2017-2028)
8.2 Asia Pacific Cetuximab Biosimilar Market Size by Application
8.2.1 Asia Pacific Cetuximab Biosimilar Sales by Application (2017-2028)
8.2.2 Asia Pacific Cetuximab Biosimilar Revenue by Application (2017-2028)
8.3 Asia Pacific Cetuximab Biosimilar Market Size by Region
8.3.1 Asia Pacific Cetuximab Biosimilar Sales by Region (2017-2028)
8.3.2 Asia Pacific Cetuximab Biosimilar Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Cetuximab Biosimilar Market Size by Type
9.1.1 Latin America Cetuximab Biosimilar Sales by Type (2017-2028)
9.1.2 Latin America Cetuximab Biosimilar Revenue by Type (2017-2028)
9.2 Latin America Cetuximab Biosimilar Market Size by Application
9.2.1 Latin America Cetuximab Biosimilar Sales by Application (2017-2028)
9.2.2 Latin America Cetuximab Biosimilar Revenue by Application (2017-2028)
9.3 Latin America Cetuximab Biosimilar Market Size by Country
9.3.1 Latin America Cetuximab Biosimilar Sales by Country (2017-2028)
9.3.2 Latin America Cetuximab Biosimilar Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Cetuximab Biosimilar Market Size by Type
10.1.1 Middle East and Africa Cetuximab Biosimilar Sales by Type (2017-2028)
10.1.2 Middle East and Africa Cetuximab Biosimilar Revenue by Type (2017-2028)
10.2 Middle East and Africa Cetuximab Biosimilar Market Size by Application
10.2.1 Middle East and Africa Cetuximab Biosimilar Sales by Application (2017-2028)
10.2.2 Middle East and Africa Cetuximab Biosimilar Revenue by Application (2017-2028)
10.3 Middle East and Africa Cetuximab Biosimilar Market Size by Country
10.3.1 Middle East and Africa Cetuximab Biosimilar Sales by Country (2017-2028)
10.3.2 Middle East and Africa Cetuximab Biosimilar Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Actavis
11.1.1 Actavis Corporation Information
11.1.2 Actavis Overview
11.1.3 Actavis Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Actavis Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Actavis Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Overview
11.2.3 Amgen Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Amgen Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Amgen Recent Developments
11.3 Celltrion
11.3.1 Celltrion Corporation Information
11.3.2 Celltrion Overview
11.3.3 Celltrion Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Celltrion Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Celltrion Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Pfizer Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Bio X Cell
11.5.1 Bio X Cell Corporation Information
11.5.2 Bio X Cell Overview
11.5.3 Bio X Cell Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Bio X Cell Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bio X Cell Recent Developments
11.6 Wuhan Dima Biotechnology
11.6.1 Wuhan Dima Biotechnology Corporation Information
11.6.2 Wuhan Dima Biotechnology Overview
11.6.3 Wuhan Dima Biotechnology Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Wuhan Dima Biotechnology Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Wuhan Dima Biotechnology Recent Developments
11.7 Guangdong ANNPO Biotechnology
11.7.1 Guangdong ANNPO Biotechnology Corporation Information
11.7.2 Guangdong ANNPO Biotechnology Overview
11.7.3 Guangdong ANNPO Biotechnology Cetuximab Biosimilar Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Guangdong ANNPO Biotechnology Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Guangdong ANNPO Biotechnology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cetuximab Biosimilar Industry Chain Analysis
12.2 Cetuximab Biosimilar Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cetuximab Biosimilar Production Mode & Process
12.4 Cetuximab Biosimilar Sales and Marketing
12.4.1 Cetuximab Biosimilar Sales Channels
12.4.2 Cetuximab Biosimilar Distributors
12.5 Cetuximab Biosimilar Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Cetuximab Biosimilar Industry Trends
13.2 Cetuximab Biosimilar Market Drivers
13.3 Cetuximab Biosimilar Market Challenges
13.4 Cetuximab Biosimilar Market Restraints
14 Key Findings in The Global Cetuximab Biosimilar Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Cetuximab Biosimilar Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 100 mg/50 mL Injection
Table 3. Major Manufacturers of 200 mg/100 mL Injection
Table 4. Global Cetuximab Biosimilar Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Cetuximab Biosimilar Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Cetuximab Biosimilar Sales by Region (2017-2022) & (K Pcs)
Table 7. Global Cetuximab Biosimilar Sales Market Share by Region (2017-2022)
Table 8. Global Cetuximab Biosimilar Sales by Region (2023-2028) & (K Pcs)
Table 9. Global Cetuximab Biosimilar Sales Market Share by Region (2023-2028)
Table 10. Global Cetuximab Biosimilar Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Cetuximab Biosimilar Revenue Market Share by Region (2017-2022)
Table 12. Global Cetuximab Biosimilar Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Cetuximab Biosimilar Revenue Market Share by Region (2023-2028)
Table 14. Global Cetuximab Biosimilar Sales by Manufacturers (2017-2022) & (K Pcs)
Table 15. Global Cetuximab Biosimilar Sales Share by Manufacturers (2017-2022)
Table 16. Global Cetuximab Biosimilar Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Cetuximab Biosimilar Revenue Share by Manufacturers (2017-2022)
Table 18. Cetuximab Biosimilar Price by Manufacturers (2017-2022) &(US$/Pcs)
Table 19. Global Cetuximab Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Cetuximab Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cetuximab Biosimilar as of 2021)
Table 21. Cetuximab Biosimilar Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Cetuximab Biosimilar Product Offered
Table 23. Date of Manufacturers Enter into Cetuximab Biosimilar Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 26. Global Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 27. Global Cetuximab Biosimilar Sales Share by Type (2017-2022)
Table 28. Global Cetuximab Biosimilar Sales Share by Type (2023-2028)
Table 29. Global Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Cetuximab Biosimilar Revenue Share by Type (2017-2022)
Table 32. Global Cetuximab Biosimilar Revenue Share by Type (2023-2028)
Table 33. Cetuximab Biosimilar Price by Type (2017-2022) & (US$/Pcs)
Table 34. Global Cetuximab Biosimilar Price Forecast by Type (2023-2028) & (US$/Pcs)
Table 35. Global Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 36. Global Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 37. Global Cetuximab Biosimilar Sales Share by Application (2017-2022)
Table 38. Global Cetuximab Biosimilar Sales Share by Application (2023-2028)
Table 39. Global Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Cetuximab Biosimilar Revenue Share by Application (2017-2022)
Table 42. Global Cetuximab Biosimilar Revenue Share by Application (2023-2028)
Table 43. Cetuximab Biosimilar Price by Application (2017-2022) & (US$/Pcs)
Table 44. Global Cetuximab Biosimilar Price Forecast by Application (2023-2028) & (US$/Pcs)
Table 45. North America Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 46. North America Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 47. North America Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 50. North America Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 51. North America Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Cetuximab Biosimilar Sales by Country (2017-2022) & (K Pcs)
Table 54. North America Cetuximab Biosimilar Sales by Country (2023-2028) & (K Pcs)
Table 55. North America Cetuximab Biosimilar Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Cetuximab Biosimilar Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 58. Europe Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 59. Europe Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 62. Europe Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 63. Europe Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Cetuximab Biosimilar Sales by Country (2017-2022) & (K Pcs)
Table 66. Europe Cetuximab Biosimilar Sales by Country (2023-2028) & (K Pcs)
Table 67. Europe Cetuximab Biosimilar Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Cetuximab Biosimilar Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 70. Asia Pacific Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 71. Asia Pacific Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 74. Asia Pacific Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 75. Asia Pacific Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Cetuximab Biosimilar Sales by Region (2017-2022) & (K Pcs)
Table 78. Asia Pacific Cetuximab Biosimilar Sales by Region (2023-2028) & (K Pcs)
Table 79. Asia Pacific Cetuximab Biosimilar Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Cetuximab Biosimilar Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 82. Latin America Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 83. Latin America Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 86. Latin America Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 87. Latin America Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Cetuximab Biosimilar Sales by Country (2017-2022) & (K Pcs)
Table 90. Latin America Cetuximab Biosimilar Sales by Country (2023-2028) & (K Pcs)
Table 91. Latin America Cetuximab Biosimilar Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Cetuximab Biosimilar Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Cetuximab Biosimilar Sales by Type (2017-2022) & (K Pcs)
Table 94. Middle East and Africa Cetuximab Biosimilar Sales by Type (2023-2028) & (K Pcs)
Table 95. Middle East and Africa Cetuximab Biosimilar Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Cetuximab Biosimilar Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Cetuximab Biosimilar Sales by Application (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Cetuximab Biosimilar Sales by Application (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Cetuximab Biosimilar Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Cetuximab Biosimilar Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Cetuximab Biosimilar Sales by Country (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Cetuximab Biosimilar Sales by Country (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Cetuximab Biosimilar Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Cetuximab Biosimilar Revenue by Country (2023-2028) & (US$ Million)
Table 105. Actavis Corporation Information
Table 106. Actavis Description and Major Businesses
Table 107. Actavis Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 108. Actavis Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Actavis Recent Developments
Table 110. Amgen Corporation Information
Table 111. Amgen Description and Major Businesses
Table 112. Amgen Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 113. Amgen Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Amgen Recent Developments
Table 115. Celltrion Corporation Information
Table 116. Celltrion Description and Major Businesses
Table 117. Celltrion Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 118. Celltrion Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Celltrion Recent Developments
Table 120. Pfizer Corporation Information
Table 121. Pfizer Description and Major Businesses
Table 122. Pfizer Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 123. Pfizer Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Pfizer Recent Developments
Table 125. Bio X Cell Corporation Information
Table 126. Bio X Cell Description and Major Businesses
Table 127. Bio X Cell Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 128. Bio X Cell Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Bio X Cell Recent Developments
Table 130. Wuhan Dima Biotechnology Corporation Information
Table 131. Wuhan Dima Biotechnology Description and Major Businesses
Table 132. Wuhan Dima Biotechnology Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 133. Wuhan Dima Biotechnology Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Wuhan Dima Biotechnology Recent Developments
Table 135. Guangdong ANNPO Biotechnology Corporation Information
Table 136. Guangdong ANNPO Biotechnology Description and Major Businesses
Table 137. Guangdong ANNPO Biotechnology Cetuximab Biosimilar Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2017-2022)
Table 138. Guangdong ANNPO Biotechnology Cetuximab Biosimilar Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Guangdong ANNPO Biotechnology Recent Developments
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Cetuximab Biosimilar Distributors List
Table 143. Cetuximab Biosimilar Customers List
Table 144. Cetuximab Biosimilar Market Trends
Table 145. Cetuximab Biosimilar Market Drivers
Table 146. Cetuximab Biosimilar Market Challenges
Table 147. Cetuximab Biosimilar Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Cetuximab Biosimilar Product Picture
Figure 3. Global Cetuximab Biosimilar Market Share by Type in 2021 & 2028
Figure 3. 100 mg/50 mL Injection Product Picture
Figure 4. 200 mg/100 mL Injection Product Picture
Figure 5. Global Cetuximab Biosimilar Market Share by Application in 2021 & 2028
Figure 6. Metastatic colorectal cancer
Figure 7. Metastatic breast cancer
Figure 8. Non-small cell lung cancer
Figure 9. Other
Figure 10. Cetuximab Biosimilar Report Years Considered
Figure 11. Global Cetuximab Biosimilar Sales 2017-2028 (K Pcs)
Figure 12. Global Cetuximab Biosimilar Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Cetuximab Biosimilar Revenue 2017-2028 (US$ Million)
Figure 14. Global Cetuximab Biosimilar Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Cetuximab Biosimilar Sales Market Share by Region (2017-2022)
Figure 16. Global Cetuximab Biosimilar Sales Market Share by Region (2023-2028)
Figure 17. North America Cetuximab Biosimilar Sales YoY (2017-2028) & (K Pcs)
Figure 18. North America Cetuximab Biosimilar Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Cetuximab Biosimilar Sales YoY (2017-2028) & (K Pcs)
Figure 20. Europe Cetuximab Biosimilar Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Cetuximab Biosimilar Sales YoY (2017-2028) & (K Pcs)
Figure 22. Asia-Pacific Cetuximab Biosimilar Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Cetuximab Biosimilar Sales YoY (2017-2028) & (K Pcs)
Figure 24. Latin America Cetuximab Biosimilar Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Cetuximab Biosimilar Sales YoY (2017-2028) & (K Pcs)
Figure 26. Middle East & Africa Cetuximab Biosimilar Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Cetuximab Biosimilar Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Cetuximab Biosimilar in the World: Market Share by Cetuximab Biosimilar Revenue in 2021
Figure 29. Global Cetuximab Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 31. Global Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 32. Global Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 33. Global Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 34. North America Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 35. North America Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 36. North America Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 37. North America Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 38. North America Cetuximab Biosimilar Sales Share by Country (2017-2028)
Figure 39. North America Cetuximab Biosimilar Revenue Share by Country (2017-2028)
Figure 40. United States Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 43. Europe Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 44. Europe Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 45. Europe Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 46. Europe Cetuximab Biosimilar Sales Share by Country (2017-2028)
Figure 47. Europe Cetuximab Biosimilar Revenue Share by Country (2017-2028)
Figure 48. Germany Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 49. France Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Cetuximab Biosimilar Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Cetuximab Biosimilar Revenue Share by Region (2017-2028)
Figure 59. China Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 62. India Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 69. Latin America Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 71. Latin America Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Cetuximab Biosimilar Sales Share by Country (2017-2028)
Figure 73. Latin America Cetuximab Biosimilar Revenue Share by Country (2017-2028)
Figure 74. Mexico Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Cetuximab Biosimilar Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Cetuximab Biosimilar Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Cetuximab Biosimilar Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Cetuximab Biosimilar Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Cetuximab Biosimilar Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Cetuximab Biosimilar Revenue Share by Country (2017-2028)
Figure 84. Turkey Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Cetuximab Biosimilar Revenue (2017-2028) & (US$ Million)
Figure 87. Cetuximab Biosimilar Value Chain
Figure 88. Cetuximab Biosimilar Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のセツキシマブバイオシミラー市場インサイト及び予測（100 mg / 50 mL注射、200 mg /100mL注射）(Global Cetuximab Biosimilar Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 細胞療法用細胞凍結培地のグローバル市場2023年：血清含有凍結培地、無血清凍結培地
  • クレアチンキナーゼアッセイキットのグローバル市場2023年：酵素結合法、比色法
  • テノキシカムAPIのグローバル市場2023年：純度≧99%、純度≧99.5%
  • 世界の試料保存液市場インサイト及び予測（非不活化試料保存液、不活化試料保存液）
  • 世界のトランスフェクション培地市場インサイト及び予測（液体トランスフェクションメディウム、乾燥粉体トランスフェクションメディウム）